LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News NEWS FLASH L impact Sep 24, 2026, 10:00 AM UTC

BDSX - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

BDSX

Related stories

Ratti H1 Net Loss €4.6 Mln Ratti SpA Sb MIL:RAT L impact | NEWS | Sep 24, 2026, 12:24 PM UTC Qualcomm, Apple Renew Global Patent License Agreement By Connor HartQualcomm renewed its global patent license agreement with Apple, effective April 1, 2027.The terms and duration of the pact weren't disclosed.The partnership between L impact | NEWS | Sep 24, 2026, 12:23 PM UTC OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) New York, New York and Rockville, Maryland--(. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, L impact | NEWS | Sep 24, 2026, 12:22 PM UTC Maruti Suzuki commissions 300 kW Green Hydrogen plant at Manesar Country’s largest passenger vehicles makers, Maruti Suzuki India (MSIL) on Thursday said it has commissioned 300 kW Green Hydrogen (GH₂) electrolyser plant, set up as pilot, at its L impact | NEWS | Sep 24, 2026, 12:21 PM UTC SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critical L impact | NEWS | Sep 24, 2026, 12:21 PM UTC Okta's Oktane Conference Leaves Mizuho Neutral Mizuho raised its price target on Okta NASDAQ:OKTA, the identity security software provider, to $200 from $165 while keeping a Neutral rating, citing momentum in agentic AI and hig L impact | NEWS | Sep 24, 2026, 12:21 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.